Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones Holders will have until December 30, 2025 to exercise Tranche A Warrants at $1.05 per share, enabling up to $17.9 million in potential gross proceeds GlobeNewswire December 15, 2025 BURLINGTON, Mass., Dec. 15, 2025 […]

CEA Industries (BNC) Reports FY Q2 2026 Earnings Results GlobeNewswire December 15, 2025 Fiscal Q2 2026 (which began on Aug 1, 2025 and ended Oct 31, 2025) included a $500M private placement, fueling BNC's digital assets treasury transformation. World's Largest BNB Treasury with over 500,000 BNB held, providing unmatched exposure to a leading digital asset

Toronto, Ontario–(Newsfile Corp. – December 15, 2025) – Volta Metals Ltd. (CSE: VLTA) (FSE: D0W) (OTC Pink: VOLMF) (“Volta” or the “Company“) is pleased to announce a non-brokered private placement to raise proceeds of up to $1,500,000 through the issuance of up to 6,521,739 common shares of the Company issued on a “flow-through” basis (the “Flow-Through

Vancouver, British Columbia–(Newsfile Corp. – December 15, 2025) – Hemisphere Energy Corporation (TSXV: HME) (OTCQX: HMENF) (“Hemisphere” or the “Company”) announces that its Board of Directors has approved grants of incentive restricted share units (“RSU”) and stock options. Restricted Share Units Under the Company’s Restricted Share Unit Plan (the “Plan”), RSUs may be granted to directors, employees,

Titomic Limited (ASX: TTT), a global leader in cold spray additive manufacturing utilizing their Titomic Kinetic Fusion™ technology, is pleased to announce it has secured an Early Manufacturing Development (EMD) contract with a leading defense prime contractor to support a new effort for production of next-generation defense articles. The collaboration will establish and validate an

NEW YORK CITY, NY / ACCESS Newswire / December 15, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ:DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead plaintiff deadline. SO WHAT:

(NASDAQ:ALLO),(Euronext Growth Paris:ALCLS),(NasdaqGM:CLLS), Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights 1H 2026 Interim Futility Analysis from the Pivotal Phase 2 ALPHA3 Trial with Cema-Cel in First-Line

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis GlobeNewswire December 15, 2025 Arbitration Ruling Reaffirms Allogene's Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene's Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights 1H 2026 Interim Futility

The gene therapies for cardiomyopathies market is poised for strong growth as advancements in genomic medicine accelerate the development of targeted treatments for inherited and acquired cardiac disorders. Additionally, emerging candidates such as LX2020 and LX2006 from Lexeo Therapeutics and AB-1002 from AskBio exemplify targeted, mechanism-driven strategies aimed at correcting or compensating for underlying genetic

NEW YORK CITY, NY / ACCESS Newswire / December 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of The Home Depot, Inc. ("Home Depot" or the "Company") (NYSE:HD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Home Depot and certain of